TY - JOUR
T1 - Acute-on-chronic liver failure (ACLF)
T2 - the ‘Kyoto Consensus’—steps from Asia
AU - APASL-ACLF Research Consortium (AARC) for APASL-ACLF working party
AU - Choudhury, Ashok
AU - Kulkarni, Anand V.
AU - Arora, Vinod
AU - Soin, A. S.
AU - Dokmeci, Abdul Kadir
AU - Chowdhury, Abhijeet
AU - Koshy, Abraham
AU - Duseja, Ajay
AU - Kumar, Ajay
AU - Mishra, Ajay Kumar
AU - Patwa, Ajay Kumar
AU - Sood, Ajit
AU - Roy, Akash
AU - Shukla, Akash
AU - Chan, Albert
AU - Krag, Aleksander
AU - Mukund, Amar
AU - Mandot, Ameet
AU - Goel, Amit
AU - Butt, Amna Subhan
AU - Sahney, Amrish
AU - Shrestha, Ananta
AU - Cárdenas, Andrés
AU - Di Giorgio, Angelo
AU - Arora, Anil
AU - Anand, Anil Chandra
AU - Dhawan, Anil
AU - Jindal, Ankur
AU - Saraya, Anoop
AU - Srivastava, Anshu
AU - Kumar, Anupam
AU - Kaewdech, Apichat
AU - Pande, Apurva
AU - Rastogi, Archana
AU - Valsan, Arun
AU - Goel, Ashish
AU - Kumar, Ashish
AU - Singal, Ashwani K.
AU - Tanaka, Atsushi
AU - Coilly, Audrey
AU - Singh, Ayaskanta
AU - Meena, Babu Lal
AU - Jagadisan, Barath
AU - Sharma, Barjesh Chander
AU - Lal, Bikrant Bihari
AU - Eapen, C. E.
AU - Yaghi, Cesar
AU - Kedarisetty, Chandan Kumar
AU - Kim, Chang Wook
AU - Tanwandee, Tawesak
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/2
Y1 - 2025/2
N2 - Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set in 2004 on ACLF was published in 2009, and the “APASL ACLF Research Consortium (AARC)” was formed in 2012. The AARC database has prospectively collected nearly 10,500 cases of ACLF from various countries in the Asia–Pacific region. This database has been instrumental in developing the AARC score and grade of ACLF, the concept of the ‘Golden Therapeutic Window’, the ‘transplant window’, and plasmapheresis as a treatment modality. Also, the data has been key to identifying pediatric ACLF. The European Association for the Study of Liver-Chronic Liver Failure (EASL CLIF) and the North American Association for the Study of the End Stage Liver Disease (NACSELD) from the West added the concepts of organ failure and infection as precipitants for the development of ACLF and CLIF-Sequential Organ Failure Assessment (SOFA) and NACSELD scores for prognostication. The Chinese Group on the Study of Severe Hepatitis B (COSSH) added COSSH-ACLF criteria to manage hepatitis b virus-ACLF with and without cirrhosis. The literature supports these definitions to be equally effective in their respective cohorts in identifying patients with high mortality. To overcome the differences and to develop a global consensus, APASL took the initiative and invited the global stakeholders, including opinion leaders from Asia, EASL and AASLD, and other researchers in the field of ACLF to identify the key issues and develop an evidence-based consensus document. The consensus document was presented in a hybrid format at the APASL annual meeting in Kyoto in March 2024. The ‘Kyoto APASL Consensus’ presented below carries the final recommendations along with the relevant background information and areas requiring future studies.
AB - Acute-on-chronic liver failure (ACLF) is a condition associated with high mortality in the absence of liver transplantation. There have been various definitions proposed worldwide. The first consensus report of the working party of the Asian Pacific Association for the Study of the Liver (APASL) set in 2004 on ACLF was published in 2009, and the “APASL ACLF Research Consortium (AARC)” was formed in 2012. The AARC database has prospectively collected nearly 10,500 cases of ACLF from various countries in the Asia–Pacific region. This database has been instrumental in developing the AARC score and grade of ACLF, the concept of the ‘Golden Therapeutic Window’, the ‘transplant window’, and plasmapheresis as a treatment modality. Also, the data has been key to identifying pediatric ACLF. The European Association for the Study of Liver-Chronic Liver Failure (EASL CLIF) and the North American Association for the Study of the End Stage Liver Disease (NACSELD) from the West added the concepts of organ failure and infection as precipitants for the development of ACLF and CLIF-Sequential Organ Failure Assessment (SOFA) and NACSELD scores for prognostication. The Chinese Group on the Study of Severe Hepatitis B (COSSH) added COSSH-ACLF criteria to manage hepatitis b virus-ACLF with and without cirrhosis. The literature supports these definitions to be equally effective in their respective cohorts in identifying patients with high mortality. To overcome the differences and to develop a global consensus, APASL took the initiative and invited the global stakeholders, including opinion leaders from Asia, EASL and AASLD, and other researchers in the field of ACLF to identify the key issues and develop an evidence-based consensus document. The consensus document was presented in a hybrid format at the APASL annual meeting in Kyoto in March 2024. The ‘Kyoto APASL Consensus’ presented below carries the final recommendations along with the relevant background information and areas requiring future studies.
KW - AARC
KW - ACLF
KW - Acute decompensation (AD)
KW - Cirrhosis
KW - Non-acute decompensation (NAD)
KW - Organ failure
KW - Recompensation
UR - http://www.scopus.com/inward/record.url?scp=85219757138&partnerID=8YFLogxK
U2 - 10.1007/s12072-024-10773-4
DO - 10.1007/s12072-024-10773-4
M3 - Article
C2 - 39961976
AN - SCOPUS:85219757138
SN - 1936-0533
VL - 19
SP - 1
EP - 69
JO - Hepatology International
JF - Hepatology International
IS - 1
M1 - 101140
ER -